QIAGEN Banks On Tie-Ups & Product Launches, Competition Rife
Zacks Investment Research | Oct 10, 2017 09:55PM ET
On Oct 10, we issued an updated research report on Netherlands-based molecular diagnostics provider QIAGEN (NASDAQ:QGEN) . The company offers innovative technologies and products for pre-analytical sample preparation and molecular diagnostics solutions.
We are upbeat about QIAGEN’s partnership and co-marketing agreement with CENTOGENE AG to boost its bioinformatics portfolio. Also, we are encouraged to note that post the receipt of FDA approval in June, QIAGEN announced the complete launch of the fourth generation of its blood test for tuberculosis (TB) infection — QuantiFERON-TB Gold Plus (QFT-Plus) — in the United States.
Moreover, the company’s strategic focus to drive growth through Sample to Insight offerings buoys optimism. QIAGEN is forming collaborations in the personalized homecare space as well.
QIAGEN currently markets products in more than 100 countries. In the last reported second quarter of 2017, the company witnessed growth across all international regions, including the top seven emerging markets.
On the flip side, over the last three months, QIAGEN has been trading below the broader Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.